Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "Chief-Executive-Officer"

898 News Found

W.R. Grace to expand capacity at small-molecule API plant
News | July 13, 2022

W.R. Grace to expand capacity at small-molecule API plant

The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction


SRL Diagnostics launches fatty liver index
Clinical Trials | July 13, 2022

SRL Diagnostics launches fatty liver index

An algorithm based testing for Fatty Liver Disease


Piramal Pharma Solutions holds opening ceremony for new API Plant at Aurora, Canada
News | July 13, 2022

Piramal Pharma Solutions holds opening ceremony for new API Plant at Aurora, Canada

Plant is part of the company's CAD $30 million capital investment in the site


ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services
News | July 13, 2022

ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services

Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B


ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India
People | July 05, 2022

ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India

Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.


Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
Healthcare | July 05, 2022

Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Medicines, including insulin, to be available in 40 lower-income countries


OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212
Drug Approval | July 04, 2022

OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212

The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.


Pfizer submits new drug application to the U.S. FDA for Paxlovid
Drug Approval | July 03, 2022

Pfizer submits new drug application to the U.S. FDA for Paxlovid

Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk


Pfizer to achieve net-zero standard by 2040
Sustainability | July 03, 2022

Pfizer to achieve net-zero standard by 2040

Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard


Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
News | July 02, 2022

Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners

HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States